12.7.26 Community-Based Treatment for Opioid Use Disorder: Models, Access, and the Path Forward
Activity Announcement
Community-Based Treatment for Opioid Use Disorder: Models, Access, and the Path Forward
Monday, December 7, 2026
12:00 pm – 1:00 pm
FREE, live Zoom Webinar
Hosted by Maryland Addiction Consultation Service (MACS)
Schedule:
|
Time
|
Content
|
|
12:00pm – 12:05pm
|
Introduction and overview of credit process
|
|
12:05pm – 12:20pm
|
Learning Objective #1:
Describe the major models of community-based treatment for opioid use disorder — including office-based buprenorphine, opioid treatment programs (methadone), and low-barrier/harm-reduction settings - and the evidence supporting medications for opioid use disorder (MOUD) in each.
|
|
12:20pm – 12:35pm
|
Learning Objective #2:
Identify common patient-, provider-, and system-level barriers to accessing and retaining patients in community-based OUD treatment, and apply strategies to facilitate effective transitions of care from the inpatient or consult setting to community providers.
|
|
12:35pm –12:50 pm
|
Learning Objective #3:
Formulate an individualized treatment linkage plan for a patient with OUD that incorporates MOUD continuation, referral to appropriate community resources, and harm-reduction interventions such as naloxone distribution.
|
|
12:50 pm–1:00 pm
|
Participant and Presenter Q&A
|
| |
|
Speaker:
Will Garneau, MD, MPH, MHS
Dr. William Garneau is a native of Durham, North Carolina. He graduated from Yale University with a degree in English and served as a middle school teacher in the Peace Corps in Namibia. He is a graduate of the University of North Carolina School of Medicine and earned a Master of Public Health at the UNC Gillings School of Global Public Health. He completed internal medicine residency training at the Johns Hopkins Hospital and is an assistant professor of medicine in the Division of Hospital Medicine.
In 2023 he received a KL2 mentored Career Development award from the National Institutes of Health. He is currently enrolled in the Graduate Training Program in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.
Dr. Garneau's research uses observational data to study health outcomes including novel therapies and emerging illnesses. His prior research includes studies of mpox and COVID-19. He additionally serves as a lead informaticist with the Critical Path Institute's CURE ID project.
His clinical responsibilities include providing direct care to hospitalized patients, serving as a medicine consultant to surgical services, and attending on resident teaching teams. In addition to his clinical work, Dr. Garneau is a Barker Firm Faculty member and teaches students in the Johns Hopkins School of Medicine as well as the Osler Medical Residency Training Program.
Target Audience: Pharmacists, Medical Doctors, Doctors of Osteopathic Medicine, Advanced Practice Registered Nurses, Physician Assistants, Behavioral Health Professionals, and other members of the healthcare team.
CME Credit: 1 Contact Hour pending
CEU Credit: 1.0 Contact Hour
Social Workers:
The University of Maryland School of Medicine, National Center for School Mental Health, is authorized as a sponsor of Continuing Education Units by the Board of Maryland Social Workers and maintains responsibility for this program.
Learning Objectives:
By the end of the session, participants will be able to:
- Describe the major models of community-based treatment for opioid use disorder — including office-based buprenorphine, opioid treatment programs (methadone), and low-barrier/harm-reduction settings - and the evidence supporting medications for opioid use disorder (MOUD) in each.
- Identify common patient-, provider-, and system-level barriers to accessing and retaining patients in community-based OUD treatment, and apply strategies to facilitate effective transitions of care from the inpatient or consult setting to community providers.
- Formulate an individualized treatment linkage plan for a patient with OUD that incorporates MOUD continuation, referral to appropriate community resources, and harm-reduction interventions such as naloxone distribution.
